SEC 13F Intelligence

Orbimed Advisors LLC / XENE

Orbimed Advisors LLC’s Xenon Pharmaceuticals Inc Position

Does Orbimed Advisors LLC own Xenon Pharmaceuticals Inc (XENE)? Yes — 1.06M shares worth $62M (+1.22% of its 13F portfolio) as of Q1 2026, up from 447.2K shares the prior filed quarter.

Position Value
$62M
Q1 2026
Shares
1.06M
% of Portfolio
+1.22%
Quarters Held
30
currently held

Position History XENE

Reported value by quarter
Q4 ’18: $4MQ4 ’18Q1 ’19: $6MQ2 ’19: $6MQ3 ’19: $6MQ4 ’19: $8MQ4 ’19Q1 ’20: $19MQ2 ’20: $31MQ3 ’20: $28MQ4 ’20: $38MQ4 ’20Q1 ’21: $45MQ2 ’21: $25MQ3 ’21: $7MQ4 ’21: $20MQ4 ’21Q1 ’22: $21MQ2 ’22: $40MQ3 ’22: $41MQ4 ’22: $45MQ4 ’22Q1 ’23: $41MQ2 ’23: $42MQ3 ’23: $33MQ4 ’23: $25MQ4 ’23Q1 ’24: $24MQ2 ’24: $34MQ3 ’24: $36MQ4 ’24: $37MQ4 ’24Q1 ’25: $32MQ2 ’25: $30MQ3 ’25: $17MQ4 ’25: $20MQ4 ’25Q1 ’26: $62Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.06M$62M+1.22%
Q4 2025447.2K$20M+0.41%
Q3 2025419.6K$17M+0.40%
Q2 2025947.9K$30M+0.74%
Q1 2025947.9K$32M+0.76%
Q4 2024947.9K$37M+0.76%
Q3 2024911.4K$36M+0.65%
Q2 2024862.4K$34M+0.66%
Q1 2024550.0K$24M+0.43%
Q4 2023550.0K$25M+0.51%
Q3 2023958.8K$33M+0.70%
Q2 20231.10M$42M+0.76%
Q1 20231.15M$41M+0.81%
Q4 20221.15M$45M+0.87%
Q3 20221.14M$41M+0.76%
Q2 20221.33M$40M+0.73%
Q1 2022686.0K$21M+0.34%
Q4 2021631.0K$20M+0.25%
Q3 2021477.0K$7M+0.08%
Q2 20211.33M$25M+0.25%
Q1 20212.50M$45M+0.42%
Q4 20202.50M$38M+0.34%
Q3 20202.50M$28M+0.35%
Q2 20202.50M$31M+0.44%
Q1 20201.66M$19M+0.32%
Q4 2019634.8K$8M+0.12%
Q3 2019634.8K$6M+0.11%
Q2 2019634.8K$6M+0.10%
Q1 2019634.8K$6M+0.10%
Q4 2018634.8K$4M+0.07%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of XENE.